QuidelOrtho (QDEL) Fiscal Q2 EPS Beats

(NASDAQ:QDEL), a global provider of diagnostic testing solutions, released its financial results for the quarter ended June 29, 2025, on August 5, 2025. The most notable headline was a return to positive adjusted earnings per share (non-GAAP) and improved adjusted profit margins (non-GAAP), even amid continued year-over-year revenue decline. Reported GAAP revenue of $614 million beat analyst consensus of $611.1 million, and Adjusted non-GAAP earnings per share came in at $0.12, far exceeding the $0.00 consensus estimate. However, The quarter was also marked by a much larger GAAP net loss, mainly from $179 million in non-cash charges, mostly tied to discontinuing the Savanna molecular testing system. Overall, the period reflected tight expense control and some growth in core diagnostics segments, weighed down by sharply lower sales in COVID-19 and Donor Screening products, as well as heavy restructuring costs.

Source: Analyst estimates provided by FactSet. Management expectations based on management's guidance, as provided in Q1 2025 earnings report.

QuidelOrtho is a diagnostics company with a presence in over 130 countries, providing a range of products used in laboratories, hospitals, and at the point of care. It operates several platforms such as Vitros (laboratory chemistry analyzers), Sofia and Triage (point-of-care devices), and immunohematology systems for blood typing and transfusion support. QuidelOrtho’s customers include hospitals, clinical labs, blood banks, and clinics that rely on its instruments and testing supplies for patient care, disease surveillance, and screening.

Continue reading

Source Fool.com